NCT03744702 is a EARLY_PHASE1 clinical trial of Ascorbic Acid in Vasoplegia, sponsored by Mayo Clinic.

Who is sponsoring NCT03744702?

NCT03744702 is sponsored by Mayo Clinic.

What drugs are being tested in NCT03744702?

Interventions in NCT03744702: Ascorbic Acid.

What condition does NCT03744702 study?

NCT03744702 studies Vasoplegia.

Is NCT03744702 still recruiting?

NCT03744702 is currently completed. Last updated 11 March 2021.

Last reviewed 2021-03-11 · How we verify

NCT03744702

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Impact of Ascorbic Acid Treatment on the Development and Treatment of Vasodilation in Cardiac Surgery

Completed EARLY_PHASE1 Last updated 11 March 2021

What this trial tests

EARLY_PHASE1 trial testing Ascorbic Acid in Vasoplegia in 15 participants. Completed in 5 February 2021.

Timeline

28 June 2019

Primary endpoint
5 February 2021

5 February 2021

Quick facts

Lead sponsor	Mayo Clinic
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	15
Start date	28 June 2019
Primary completion	5 February 2021
Estimated completion	5 February 2021
Sites	1 location across United States

Drugs / interventions tested

Ascorbic Acid (ASCORBIC ACID) — full drug profile →

Conditions studied

Vasoplegia — all drugs for Vasoplegia →

Sponsor

Mayo Clinic

Who can join

18 and older, any sex, with Vasoplegia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective pilot study in which the effects of ascorbic acid administration are investigated in adult patients undergoing cardiac surgical procedures requiring cardiopulmonary bypass (CPB). Ascorbic acid (Vitamin C) is an essential cofactor in the biosynthesis of catecholamines, and critically ill patients are known to be ascorbate-deficient. In addition, cardiopulmonary bypass (CPB) decreases ascorbic acid concentrations. Cardiac vasoplegia is the loss of vascular tone despite adequate volume status and cardiac output, occurring commonly in patients after CPB. This necessitates the administration of vasopressors and alternative agents which can have deleterious effects. The administration of ascorbic acid to cardiac surgical patients may improve microcirculatory function, enhance endogenous catecholamine levels and decrease the need for exogenous vasopressor support.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Ascorbic acid and microcirculation in cardiothoracic surgery: a pilot feasibility trial and matched cohort study.
Wieruszewski PM, Radosevich MA, Nei SD, Kashani KB, et al · · 2025 · PMID 40400032 · DOI 10.1186/s13019-025-03486-8

Verify or expand the search:

Other trials of Ascorbic Acid

Trials testing the same drug.

NCT03066115 — Impact of NOS, COX, and ROS Inhibition on Cerebral Blood Flow Regulation · Phase 1 · withdrawn
NCT04138394 — VItamin C in Thermal injuRY: The VICToRY Trial · Phase 3 · suspended
NCT04354428 — Treatment for COVID-19 in High-Risk Adult Outpatients · Phase 2, PHASE3 · terminated
NCT04342728 — Coronavirus 2019 (COVID-19)- Using Ascorbic Acid and Zinc Supplementation · NA · completed
NCT04328961 — Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP) · Phase 2, PHASE3 · completed

Other recruiting trials for Vasoplegia

Currently open trials in the same condition.

NCT06952907 — Femoral Versus Radial Invasive Arterial Pressure Monitoring in Cardiac Surgery Patients · NA · recruiting
NCT06613256 — Characterisation of Endothelial Cells in Different Inflammatory Pathologies · recruiting
NCT04901169 — Angiotensin II in Liver Transplantation · Phase 2, PHASE3 · active not recruiting

Other Mayo Clinic trials

Trials by the same sponsor.

NCT07126548 — A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men · NA · not yet recruiting
NCT07221656 — Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration · not yet recruiting
NCT06891001 — The Utilization of a Shoe Insert on Individuals With Unilateral Greater Trochanteric Pain Syndrome on Single Leg Stance, · NA · not yet recruiting
NCT07169799 — Impact of Cryotherapy Spray (Tru-Freeze) for the Eradication of Gastric Antral Vascular Ectasia (ICE-GAVE) · NA · recruiting
NCT07086183 — Perioperative Risk in Patients on Chronic Aspirin Undergoing Craniotomy · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03744702 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mayo Clinic
Last refreshed: 11 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03744702.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing